LIVIVO - Search results -

Search results

Result 1 - 10 of total 29

Search options

Article ; Online: Chromatin Remodeling in the Brain-a

Larrigan, Sarah / Shah, Sujay / Fernandes, Alex / Mattar, Pierre

International journal of molecular sciences

2021 Volume 22, Issue 9

Abstract: During brain development, the genome must be repeatedly reconfigured in order to facilitate neuronal and glial differentiation. A host of chromatin remodeling complexes facilitates this process. At the genetic level, the non-redundancy of these complexes ...

Abstract	During brain development, the genome must be repeatedly reconfigured in order to facilitate neuronal and glial differentiation. A host of chromatin remodeling complexes facilitates this process. At the genetic level, the non-redundancy of these complexes suggests that neurodevelopment may require a lexicon of remodelers with different specificities and activities. Here, we focus on the nucleosome remodeling and deacetylase (NuRD) complex. We review NuRD biochemistry, genetics, and functions in neural progenitors and neurons.
MeSH term(s)	Animals ; Brain/embryology ; Brain/growth & development ; Brain/metabolism ; Chromatin Assembly and Disassembly ; Humans ; Mi-2 Nucleosome Remodeling and Deacetylase Complex/genetics ; Mi-2 Nucleosome Remodeling and Deacetylase Complex/metabolism ; Neural Stem Cells/cytology ; Neural Stem Cells/metabolism ; Neurogenesis ; Neurons/cytology ; Neurons/metabolism
Chemical Substances	Mi-2 Nucleosome Remodeling and Deacetylase Complex (EC 3.5.1.98)
Language	English
Publishing date	2021-04-30
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2019364-6
ISSN	1422-0067 ; 1422-0067 ; 1661-6596
ISSN (online)	1422-0067
ISSN	1422-0067 ; 1661-6596
DOI	10.3390/ijms22094768
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article: Application of robotic technologies in lower gastrointestinal tract endoscopy: A systematic review.

Sekhon Inderjit Singh, Harpreet Kaur / Armstrong, Emily Rose / Shah, Sujay / Mirnezami, Reza

World journal of gastrointestinal endoscopy

2022 Volume 13, Issue 12, Page(s) 673–697

Abstract: Background: Conventional optical colonoscopy is considered the gold standard investigation for colorectal tract pathology including colorectal malignancy, polyps and inflammatory bowel disease. Inherent limitations exist with current generation ... ...

Abstract	Background: Conventional optical colonoscopy is considered the gold standard investigation for colorectal tract pathology including colorectal malignancy, polyps and inflammatory bowel disease. Inherent limitations exist with current generation endoscopic technologies, including, but not limited to, patient discomfort, endoscopist fatigue, narrow field of view and missed pathology behind colonic folds. Rapid developments in medical robotics have led to the emergence of a variety of next-generation robotically-augmented technologies that could overcome these limitations. Aim: To provide a comprehensive summary of recent developments in the application of robotics in lower gastrointestinal tract endoscopy. Methods: A systematic review of the literature was performed from January 1, 2000 to the January 7, 2021 using EMBASE, MEDLINE and Cochrane databases. Studies reporting data on the use of robotic technology in Results: Initial literature searching identified 814 potentially eligible studies, from which 37 were deemed suitable for inclusion. Included studies were classified according to the actuation modality of the robotic device(s) as electromechanical (EM) ( Conclusion: Significant progress in robotic colonoscopy has been made over the last couple of decades. Improvements in design together with the integration of semi-autonomous and autonomous systems over the next decade will potentially result in robotic colonoscopy becoming more commonplace.
Language	English
Publishing date	2022-01-13
Publishing country	United States
Document type	Journal Article
ZDB-ID	2573698-X
ISSN	1948-5190
ISSN	1948-5190
DOI	10.4253/wjge.v13.i12.673
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Casz1-NuRD complex regulates temporal identity transitions in neural progenitors.

Mattar, Pierre / Jolicoeur, Christine / Dang, Thanh / Shah, Sujay / Clark, Brian S / Cayouette, Michel

Scientific reports

2021 Volume 11, Issue 1, Page(s) 3858

Abstract: Neural progenitor cells undergo identity transitions during development to ensure the generation different types of neurons and glia in the correct sequence and proportions. A number of temporal identity factors that control these transitions in ... ...

Abstract	Neural progenitor cells undergo identity transitions during development to ensure the generation different types of neurons and glia in the correct sequence and proportions. A number of temporal identity factors that control these transitions in progenitor competence have been identified, but the molecular mechanisms underlying their function remain unclear. Here, we asked how Casz1, the mammalian orthologue of Drosophila castor, regulates competence during retinal development. We show that Casz1 is required to control the transition between neurogenesis and gliogenesis. Using BioID proteomics, we reveal that Casz1 interacts with the nucleosome remodeling and deacetylase (NuRD) complex in retinal cells. Finally, we show that both the NuRD and the polycomb repressor complexes are required for Casz1 to promote the rod fate and suppress gliogenesis. As additional temporal identity factors have been found to interact with the NuRD complex in other contexts, we propose that these factors might act through this common biochemical process to regulate neurogenesis.
MeSH term(s)	Animals ; DNA-Binding Proteins/metabolism ; Ependymoglial Cells ; Mi-2 Nucleosome Remodeling and Deacetylase Complex/metabolism ; Mice ; Mice, Knockout ; Neural Stem Cells/physiology ; Neurogenesis ; Polycomb-Group Proteins/metabolism ; Retina/cytology ; Retina/embryology ; Transcription Factors/metabolism
Chemical Substances	CASZ1 protein, mouse ; DNA-Binding Proteins ; Polycomb-Group Proteins ; Transcription Factors ; Mi-2 Nucleosome Remodeling and Deacetylase Complex (EC 3.5.1.98)
Language	English
Publishing date	2021-02-16
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't
ZDB-ID	2615211-3
ISSN	2045-2322 ; 2045-2322
ISSN (online)	2045-2322
ISSN	2045-2322
DOI	10.1038/s41598-021-83395-7
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Clinical and radiographic evaluation of demineralized freeze-dried bone allograft with concentrated growth factor versus concentrated growth factor alone in the treatment of intrabony defects.

Vaid, Tithi / Kumar, Santosh / Mehta, Rupal / Shah, Sujay / Joshi, Surabhi / Bhakkand, Susmita / Hirani, Tanvi

Medicine and pharmacy reports

2021 Volume 94, Issue 2, Page(s) 220–228

Abstract: Background: Periodontal disease is one of the major causes of alveolar bone loss. There are various ways of regenerating the lost bone, i.e. guided tissue regeneration, bone grafts, and growth factors. In this purview, it becomes immensely important for ...

Abstract	Background: Periodontal disease is one of the major causes of alveolar bone loss. There are various ways of regenerating the lost bone, i.e. guided tissue regeneration, bone grafts, and growth factors. In this purview, it becomes immensely important for a clinician to decide the best modality of treatment. In this study, we compared the effect of demineralized freeze-dried bone allograft (DFDBA) in combination with concentrated growth factors (CGF) verses CGF alone. Methods: This double-blind, split-mouth study was conducted on ten patients with two comparable bilateral intrabony defects. Each pair of defects was randomly treated by DFDBA + CGF or CGF alone. Clinical parameters such as plaque index (PI), modified gingival index (MGI), pocket probing depth (PPD), and relative attachment level (RAL) were recorded at baseline, three months, and six months. In addition, radiograph with grids was also taken at baseline and six months. The paired t-test was used to compare the pre- and post-treatment values and the unpaired t-test was used to compare the test and control group. Results: The PI score decreased significantly from baseline to six months. Similarly, the mean MGI score decreased significantly from baseline to six months. The intragroup comparison showed that there was a significant reduction in PPD in both the test and control group. However, the intergroup comparison showed that the reduced pocket depth was not significant. The intragroup radiographic comparison showed that there was the significant formation of bone in both the test and control group but inter-group showed that the formation of bone among both the group were non-significant. Conclusion: Radiographic and clinical outcomes of this study concluded that post six months, both groups demonstrated significant improvement in clinical and radiographic parameters. However, the addition of DFDBA to CGFs did not give any additional benefits.
Language	English
Publishing date	2021-04-29
Publishing country	Romania
Document type	Journal Article
ZDB-ID	2974425-8
ISSN	2668-0572 ; 2602-0807
ISSN (online)	2668-0572
ISSN	2602-0807
DOI	10.15386/mpr-1718
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2836: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Treating Public Health Dilemma of Gingival Recession by the Dehydrated Amnion Allograft: A 5-Year Longitudinal Study.

Kumar, Santosh / Hirani, Tanvi / Shah, Sujay / Mehta, Rupal / Bhakkand, Susmita R / Shishoo, Deepak

Frontiers in oral health

2020 Volume 1, Page(s) 540211

Abstract: Aim: ...

Abstract	Aim:
Language	English
Publishing date	2020-11-11
Publishing country	Switzerland
Document type	Journal Article
ISSN	2673-4842
ISSN (online)	2673-4842
DOI	10.3389/froh.2020.540211
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Socioeconomic and cultural impact of tobacco in India.

Shah, Sujay / Dave, Bela / Shah, Rutu / Mehta, Tejas R / Dave, Rutvik

Journal of family medicine and primary care

2018 Volume 7, Issue 6, Page(s) 1173–1176

Abstract: Tobacco consumed either in the form of smoke or smokeless is hazardous to the human body. Death toll due to tobacco globally, has risen to about 6.4 million annually, and is on a constant increase. Since long, tobacco consumption has been attributed to a ...

Abstract	Tobacco consumed either in the form of smoke or smokeless is hazardous to the human body. Death toll due to tobacco globally, has risen to about 6.4 million annually, and is on a constant increase. Since long, tobacco consumption has been attributed to a variety of factors including geographical variation, cultural factors and other associated variables. Earlier tobacco was considered as a taboo, but with advent of 21
Language	English
Publishing date	2018-12-20
Publishing country	India
Document type	Journal Article ; Review
ZDB-ID	2735275-4
ISSN	2278-7135 ; 2249-4863
ISSN (online)	2278-7135
ISSN	2249-4863
DOI	10.4103/jfmpc.jfmpc_36_18
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Nrf2 Transcription Factor Can Directly Regulate mTOR: LINKING CYTOPROTECTIVE GENE EXPRESSION TO A MAJOR METABOLIC REGULATOR THAT GENERATES REDOX ACTIVITY.

Bendavit, Gabriel / Aboulkassim, Tahar / Hilmi, Khalid / Shah, Sujay / Batist, Gerald

The Journal of biological chemistry

2016 Volume 291, Issue 49, Page(s) 25476–25488

Abstract: Nrf2 is a master transcription factor that regulates a wide variety of cellular proteins by recognizing and binding to antioxidant response elements (AREs) in their gene promoter regions. In this study we show that increasing cellular Nrf2 results in ... ...

Abstract	Nrf2 is a master transcription factor that regulates a wide variety of cellular proteins by recognizing and binding to antioxidant response elements (AREs) in their gene promoter regions. In this study we show that increasing cellular Nrf2 results in transcriptional activation of the gene for mTOR, which is central to the PI3K signaling pathway. This is the case in cells with normal physiological PI3K. However, in cells with abnormally active PI3K increased cellular Nrf2 levels have no effect on mTOR. ChIP assays results show that increased Nrf2 binding is associated with decreased p65 binding and H3-K27me3 signal (marker of gene repression) as well as increased H3-K4me3 signal (marker of gene activation). However, in cells with PI3K activation, no effect of cellular Nrf2 increase on mTOR transcription was observed. In these cells, increasing Nrf2 levels increases Nrf2 promoter binding marginally, whereas p65 binding and H3-K27me3 mark were significantly increased, and H3-K4me3 signal is reduced. Together, these data show for the first time that Nrf2 directly regulates mTOR transcription when the PI3K pathway is intact, whereas this function is lost when PI3K is activated. We have identified a link between the Nrf2 system of sensing environmental stress and mTOR, which is a key cellular protein in metabolism. Studies in cells with activating mutations in the PI3K pathway suggest that Nrf2 transcriptional regulation of mTOR is related to promoter binding of p65 and of methylation of histone residues permissive of transcription.
MeSH term(s)	Gene Expression Regulation/physiology ; Humans ; MCF-7 Cells ; Mutation ; NF-E2-Related Factor 2/genetics ; NF-E2-Related Factor 2/metabolism ; Oxidation-Reduction ; Phosphatidylinositol 3-Kinases/genetics ; Phosphatidylinositol 3-Kinases/metabolism ; Promoter Regions, Genetic/physiology ; Signal Transduction/physiology ; TOR Serine-Threonine Kinases/genetics ; TOR Serine-Threonine Kinases/metabolism ; Transcription Factor RelA/genetics ; Transcription Factor RelA/metabolism
Chemical Substances	NF-E2-Related Factor 2 ; NFE2L2 protein, human ; RELA protein, human ; Transcription Factor RelA ; Phosphatidylinositol 3-Kinases (EC 2.7.1.-) ; MTOR protein, human (EC 2.7.1.1) ; TOR Serine-Threonine Kinases (EC 2.7.1.1)
Language	English
Publishing date	2016-10-26
Publishing country	United States
Document type	Journal Article
ZDB-ID	2997-x
ISSN	1083-351X ; 0021-9258
ISSN (online)	1083-351X
ISSN	0021-9258
DOI	10.1074/jbc.M116.760249
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Uc I Zs.108: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: FDA Approval Summary: Atezolizumab and Durvalumab in Combination with Platinum-Based Chemotherapy in Extensive Stage Small Cell Lung Cancer.

Mathieu, Luckson / Shah, Sujay / Pai-Scherf, Lee / Larkins, Erin / Vallejo, Jonathon / Li, Xiaoxue / Rodriguez, Lisa / Mishra-Kalyani, Pallavi / Goldberg, Kirsten B / Kluetz, Paul G / Theoret, Marc R / Beaver, Julia A / Pazdur, Richard / Singh, Harpreet

The oncologist

2021 Volume 26, Issue 5, Page(s) 433–438

Abstract: The U.S. Food and Drug Administration (FDA) granted approval to atezolizumab and durvalumab in March of 2019 and 2020, respectively, for use in combination with chemotherapy for first-line treatment of patients with extensive stage small cell lung cancer. ...

Abstract	The U.S. Food and Drug Administration (FDA) granted approval to atezolizumab and durvalumab in March of 2019 and 2020, respectively, for use in combination with chemotherapy for first-line treatment of patients with extensive stage small cell lung cancer. These approvals were based on data from two randomized controlled trials, IMpower133 (atezolizumab) and CASPIAN (durvalumab). Both trials demonstrated an improvement in overall survival (OS) with anti-programmed death ligand 1 antibodies when added to platinum-based chemotherapy as compared with chemotherapy alone. In IMpower133, patients receiving atezolizumab with etoposide and carboplatin demonstrated improved OS (hazard ratio [HR], 0.70; 95% confidence interval [CI], 0.54-0.91; p = .0069), with median OS of 12.3 months compared with 10.3 months in patients receiving etoposide and carboplatin. In CASPIAN, patients receiving durvalumab with etoposide and either cisplatin or carboplatin also demonstrated improved OS (HR, 0.73; 95% CI, 0.59-0.91; p = .0047) with median OS of 13.0 months compared with 10.3 months in patients receiving etoposide and either cisplatin or carboplatin. The safety profiles of both drugs were generally consistent with known toxicities of immune-checkpoint inhibitor therapies. This review summarizes the FDA perspective and data supporting the approval of these two agents. IMPLICATIONS FOR PRACTICE: Effective therapeutic options for small cell lung cancer (SCLC) are limited, and there has been modest improvement in the overall survival (OS) of patients with SCLC over the past 3 decades. The approvals of atezolizumab and of durvalumab in combination with chemotherapy for first-line treatment of patients with extensive stage SCLC represent the first approved therapies with OS benefit for this patient population since the approval of etoposide in combination with other approved chemotherapeutic agents. Additionally, the efficacy results from IMpower133 and CASPIAN lay the groundwork for possible further evaluation in other treatment settings in this disease.
MeSH term(s)	Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Humans ; Lung Neoplasms/drug therapy ; Platinum/therapeutic use ; Small Cell Lung Carcinoma/drug therapy ; United States ; United States Food and Drug Administration
Chemical Substances	Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; durvalumab (28X28X9OKV) ; Platinum (49DFR088MY) ; atezolizumab (52CMI0WC3Y)
Language	English
Publishing date	2021-03-25
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	1409038-7
ISSN	1549-490X ; 1083-7159
ISSN (online)	1549-490X
ISSN	1083-7159
DOI	10.1002/onco.13752
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4845: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (2.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 494: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Episcleral, intrascleral, and suprachoroidal routes of ocular drug delivery - recent research advances and patents.

Gilger, Brian C / Mandal, Abhirup / Shah, Sujay / Mitra, Ashim K

Recent patents on drug delivery & formulation

2014 Volume 8, Issue 2, Page(s) 81–91

Abstract: Subconjunctival/episcleral, intrascleral, and suprachoroidal routes of drug delivery for treatment of posterior segment eye diseases have become more feasible and popular in the past few years. These routes have the advantage of bypassing the main ... ...

Abstract	Subconjunctival/episcleral, intrascleral, and suprachoroidal routes of drug delivery for treatment of posterior segment eye diseases have become more feasible and popular in the past few years. These routes have the advantage of bypassing the main barriers to topical drug penetration, the ocular surface epithelium, the conjunctivallymphatics, and in the case of deep intrascleral and suprachoroidial delivery, the sclera barrier. Many ocular drug delivery application devices, drug delivery methods, and therapeutics that have been developed for intravitreal use can also be used subconjunctivally, intrasclerally, and in the suprachoroidal space. Alternatively, site-specific devices, such microneedles, and therapeutics, such as hydrogel matrices, have been developed to enhance ocular drug delivery. This manuscript will review the recent research advances and patents on episcleral, intrascleral, and suprachoroidal routes of ocular drug delivery.
MeSH term(s)	Administration, Ophthalmic ; Animals ; Chemistry, Pharmaceutical ; Drug Delivery Systems/trends ; Eye Diseases/drug therapy ; Humans ; Patents as Topic
Language	English
Publishing date	2014-07-07
Publishing country	United Arab Emirates
Document type	Journal Article ; Review
ISSN	2212-4039
ISSN (online)	2212-4039
DOI	10.2174/187221130802140707093509
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article ; Online: Nanoparticle-based topical ophthalmic formulation for sustained release of stereoisomeric dipeptide prodrugs of ganciclovir.

Yang, Xiaoyan / Shah, Sujay J / Wang, Zhiying / Agrahari, Vibhuti / Pal, Dhananjay / Mitra, Ashim K

Drug delivery

2016 Volume 23, Issue 7, Page(s) 2399–2409

Abstract: Poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles (NP) of Val-Val dipeptide monoester prodrugs of ganciclovir (GCV) including L-Val-L-Val-GCV (LLGCV), L-Val-D-Val-GCV (LDGCV) and D-Val-L-Val-GCV (DLGCV) were formulated and dispersed in ... ...

Abstract	Poly(d,l-lactic-co-glycolic acid) (PLGA) nanoparticles (NP) of Val-Val dipeptide monoester prodrugs of ganciclovir (GCV) including L-Val-L-Val-GCV (LLGCV), L-Val-D-Val-GCV (LDGCV) and D-Val-L-Val-GCV (DLGCV) were formulated and dispersed in thermosensitive PLGA-PEG-PLGA polymer gel for the treatment of herpes simplex virus type 1 (HSV-1)-induced viral corneal keratitis. Nanoparticles containing prodrugs of GCV were prepared by a double-emulsion solvent evaporation technique using various PLGA polymers with different drug/polymer ratios. Nanoparticles were characterized with respect to particle size, entrapment efficiency, polydispersity, drug loading, surface morphology, zeta potential and crystallinity. Prodrugs-loaded NP were incorporated into in situ gelling system. These formulations were examined for in vitro release and cytotoxicity. The results of optimized entrapment efficiencies of LLGCV-, LDGCV- and DLGCV-loaded NP are of 38.7 ± 2.0%, 41.8 ± 1.9%, and 45.3 ± 2.2%; drug loadings 3.87 ± 0.20%, 2.79 ± 0.13% and 3.02 ± 0.15%; yield 85.2 ± 3.0%, 86.9 ± 4.6% and 76.9 ± 2.1%; particle sizes 116.6 ± 4.5, 143.0 ± 3.8 and 134.1 ± 5.2 nm; and zeta potential -15.0 ± 4.96, -13.8 ± 5.26 and -13.9 ± 5.14 mV, respectively. Cytotoxicity studies suggested that all the formulations are non-toxic. In vitro release of prodrugs from NP showed a biphasic release pattern with an initial burst phase followed by a sustained phase. Such burst effect was completely eliminated when NP were suspended in thermosensitive gels with near zero-order release kinetics. Prodrugs-loaded PLGA NP dispersed in thermosensitive gels can thus serve as a promising drug delivery system for the treatment of anterior eye diseases.
MeSH term(s)	Administration, Ophthalmic ; Delayed-Action Preparations/administration & dosage ; Delayed-Action Preparations/chemistry ; Dipeptides/administration & dosage ; Dipeptides/chemistry ; Drug Delivery Systems/methods ; Emulsions ; Eye Diseases/drug therapy ; Ganciclovir/administration & dosage ; Ganciclovir/chemistry ; Gels/administration & dosage ; Gels/chemistry ; Lactic Acid/administration & dosage ; Lactic Acid/chemistry ; Microspheres ; Nanoparticles/chemistry ; Particle Size ; Polyesters/administration & dosage ; Polyesters/chemistry ; Polyethylene Glycols/administration & dosage ; Polyethylene Glycols/chemistry ; Polyglycolic Acid/administration & dosage ; Polyglycolic Acid/chemistry ; Prodrugs/chemistry
Chemical Substances	Delayed-Action Preparations ; Dipeptides ; Emulsions ; Gels ; Polyesters ; Prodrugs ; polyethylene glycol-poly(lactide-co-glycolide) ; polylactic acid-polyglycolic acid copolymer ; Polyglycolic Acid (26009-03-0) ; Polyethylene Glycols (30IQX730WE) ; Lactic Acid (33X04XA5AT) ; valylvaline (3918-94-3) ; Ganciclovir (P9G3CKZ4P5)
Language	English
Publishing date	2016-09
Publishing country	England
Document type	Journal Article
ZDB-ID	1213261-5
ISSN	1521-0464 ; 1071-7544
ISSN (online)	1521-0464
ISSN	1071-7544
DOI	10.3109/10717544.2014.996833
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4252: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito